KR20030031001A - 사이클릭 우레아 화합물 및 그의 제조방법 - Google Patents

사이클릭 우레아 화합물 및 그의 제조방법 Download PDF

Info

Publication number
KR20030031001A
KR20030031001A KR1020027016995A KR20027016995A KR20030031001A KR 20030031001 A KR20030031001 A KR 20030031001A KR 1020027016995 A KR1020027016995 A KR 1020027016995A KR 20027016995 A KR20027016995 A KR 20027016995A KR 20030031001 A KR20030031001 A KR 20030031001A
Authority
KR
South Korea
Prior art keywords
group
carbamic acid
groups
formula
functional group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020027016995A
Other languages
English (en)
Korean (ko)
Inventor
길레스 귀차드
마르크 로드리게스
세르게 플라우
빈센트 세메테이
아르너드-삐에르 샤프너
장-폴 브리언드
Original Assignee
썽뜨르 나쇼날르 드 라 르쉐르쉐 씨엉띠삐끄
네오시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썽뜨르 나쇼날르 드 라 르쉐르쉐 씨엉띠삐끄, 네오시스템 filed Critical 썽뜨르 나쇼날르 드 라 르쉐르쉐 씨엉띠삐끄
Publication of KR20030031001A publication Critical patent/KR20030031001A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D259/00Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020027016995A 2000-06-13 2001-06-13 사이클릭 우레아 화합물 및 그의 제조방법 Withdrawn KR20030031001A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007507A FR2810039B1 (fr) 2000-06-13 2000-06-13 Composes urees cycliques et leur procede de preparation
FR00/07507 2000-06-13

Publications (1)

Publication Number Publication Date
KR20030031001A true KR20030031001A (ko) 2003-04-18

Family

ID=8851208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027016995A Withdrawn KR20030031001A (ko) 2000-06-13 2001-06-13 사이클릭 우레아 화합물 및 그의 제조방법

Country Status (13)

Country Link
US (1) US7186828B2 (https=)
EP (2) EP1640368A3 (https=)
JP (1) JP5054877B2 (https=)
KR (1) KR20030031001A (https=)
AT (1) ATE386728T1 (https=)
AU (2) AU6764501A (https=)
CA (2) CA2778314C (https=)
DE (1) DE60132891T2 (https=)
DK (1) DK1289968T3 (https=)
ES (1) ES2301554T3 (https=)
FR (1) FR2810039B1 (https=)
IL (1) IL153408A0 (https=)
WO (1) WO2001096318A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
CA2635356C (en) * 2005-12-29 2011-11-01 Immupharma France Sa Use of 1,3,5-triazepin-2,6-diones to treat malaria
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
JP2009522236A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー マラリアまたはエイズの処置のためのアザ複素環化合物
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
EP2548869A1 (en) * 2011-07-20 2013-01-23 Cytec Technology Corp. Process for the Synthesis of N-substituted Cyclic Alkylene Ureas
CN102911130B (zh) * 2011-08-03 2015-05-20 北京师范大学 一种一锅法合成脲四元环化合物的方法、合成的脲四元环化合物
AU2014310619B2 (en) 2013-08-21 2019-07-25 Centre National De La Recherche Scientifique (Cnrs) Peptide-oligourea chimeric compounds and methods of their use
WO2016207726A1 (en) 2015-06-22 2016-12-29 Ureka Sarl Bioinspired catalysis using oligourea helical foldamers
WO2017037142A1 (en) 2015-08-31 2017-03-09 Centre National De La Recherche Scientifique (Cnrs) Foldamer helix bundle-based molecular encapsulation
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
US12434075B2 (en) * 2021-05-11 2025-10-07 Celestial Oncology Inc. Coupled robotic radiation therapy system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847760A1 (de) * 1978-11-03 1980-05-14 Hoechst Ag Verfahren zur herstellung von 1,3,5-triaza-2,4,6-triketo-cycloheptan- 3,5-di-essigsaeureestern
US4918186A (en) * 1986-05-06 1990-04-17 Mitsui Toatsu Chemicals, Inc. Process for producing cyclic ureas
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
BR9206623A (pt) * 1991-10-11 1995-05-02 Du Pont Merck Pharma Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
US5637780A (en) 1993-03-30 1997-06-10 The Dupont Merck Pharmaceutical Company Method for preparing alkylating agents and their use for alkylating cyclic ureas
US5508400A (en) * 1994-04-20 1996-04-16 The Du Pont Merck Pharmaceutical Company Preparation of cyclic urea compounds
AU5310096A (en) * 1995-03-17 1996-10-08 Du Pont Merck Pharmaceutical Company, The Cyclic urea hiv protease inhibitors
US5532356A (en) * 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
US5532357A (en) * 1995-06-07 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas
WO1997008150A1 (en) 1995-08-22 1997-03-06 The Du Pont Merck Pharmaceutical Company Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
BR9712755A (pt) * 1996-11-08 1999-10-19 Du Pont Pharm Co Composto, composição farmacêutica, método para o tratamento de infecção por hiv e kit farmacêutico útil para o tratamento de infecção por hiv

Also Published As

Publication number Publication date
EP1640368A2 (fr) 2006-03-29
EP1289968A1 (fr) 2003-03-12
CA2778314A1 (en) 2001-12-20
US7186828B2 (en) 2007-03-06
JP2004503546A (ja) 2004-02-05
DK1289968T3 (da) 2008-06-23
US20040044199A1 (en) 2004-03-04
FR2810039B1 (fr) 2007-05-25
CA2412782A1 (en) 2001-12-20
WO2001096318A8 (fr) 2003-05-01
CA2778314C (en) 2017-01-03
FR2810039A1 (fr) 2001-12-14
DE60132891D1 (de) 2008-04-03
ATE386728T1 (de) 2008-03-15
CA2412782C (en) 2012-08-07
IL153408A0 (en) 2003-07-06
AU2001267645B2 (en) 2006-07-27
DE60132891T2 (de) 2009-03-19
JP5054877B2 (ja) 2012-10-24
WO2001096318A1 (fr) 2001-12-20
AU6764501A (en) 2001-12-24
ES2301554T3 (es) 2008-07-01
EP1289968B1 (fr) 2008-02-20
EP1640368A3 (fr) 2007-03-28

Similar Documents

Publication Publication Date Title
KR20030031001A (ko) 사이클릭 우레아 화합물 및 그의 제조방법
Dodd et al. Conversion of alcohols to protected guanidines using the Mitsunobu protocol
WO2023127869A1 (ja) N-アルキルアミノ酸、およびn-アルキルアミノ酸を含むペプチドの製造方法
US20220185846A1 (en) Methods for synthesizing beta-homoamino acids
EP3538542B1 (en) Cyclic peptides multimers targeting alpha 4beta 7 integrin
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
JP7837971B2 (ja) 前立腺特異的膜抗原(psma)リガンドの合成
EP2889295A1 (en) Oligooxopiperazines and methods of making and using them
JP2002534501A (ja) カルバミン酸の安定な新規活性化誘導体、その調製方法及び尿素調製のためのその利用
Dufour et al. ‘Clickable’2, 5-diketopiperazines as scaffolds for ligation of biomolecules: their use in Aβ inhibitor assembly
US20240287131A1 (en) Peptide
KR20190133033A (ko) 아릴로마이신 고리 유사체의 제조 방법
JPWO2019168164A1 (ja) タンパク質及び/又はペプチド修飾用分子
JP2020529472A (ja) ペプチド化合物の環化放出関連する出願の相互参照
US20090275727A1 (en) Peptide turn mimetics
JP2003516398A (ja) 大環状化合物およびそれらの使用
JP2025001050A (ja) ガニレリクス又はその塩の製造法
Suli-Vargha et al. Synthesis and antitumor activity of N-terminal proline-containing peptide-(chloroethyl) nitrosoureas
Hong Ni et al. Novel RGD Peptidomimetics Embedding 1, 2, 3-Triazole as Central Scaffold; Synthesis and αvβ3 Integrin Affinity
US6998272B2 (en) Macrocyclic compounds and their use
CA2779949A1 (en) Peptidomimetics comprising n-amino cyclic urea residues and uses thereof
Kricheldorf et al. New polymer syntheses, 3. Binding of nucleosides to basic polypeptides via isocyanato‐isothiocyanates
Suhs New guanidinium compounds for the molecular recognition of carboxylates and contributions to the synthesis of bivalent NPY Y1 receptor antagonists
US20220185841A1 (en) Method for producing peptide compound, reagent for forming protective group, and hydrazine derivative
WO2020195889A1 (ja) ピロールイミダゾール(ポリ)アミドの製造方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid